DrugDashboards

Jaythari

Deflazacort · DEFLAZACORT 30 mg/1 · Tablet · Oral · Doppel Farmaceutici S.r.l.

NDC 81806-0176-30 · 1 BOTTLE in 1 CARTON / 30 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00245-0816-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$353.52per unit
middle half $353.52–$353.52 · 742 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $353.52
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
14%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 5%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $13,031.70 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA219254
TE code
AB
Approval date
Apr 8, 2025
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Deflazacort (Tablet)

LabelerStrengthFirst seenLast seen
Doppel Farmaceutici S.r.l.DEFLAZACORT 6 mg/1Aug 28, 2026Sep 3, 2026
Upsher-Smith Laboratories, LLCDEFLAZACORT 36 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DEFLAZACORT 18 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DEFLAZACORT 6 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DEFLAZACORT 30 mg/1Jul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals NY LLCDEFLAZACORT 6 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCDEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCDEFLAZACORT 18 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCDEFLAZACORT 30 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDEFLAZACORT 30 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDEFLAZACORT 18 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDEFLAZACORT 6 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDEFLAZACORT 30 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDEFLAZACORT 18 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDEFLAZACORT 6 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
PTC Therapeutics, Inc.DEFLAZACORT 30 mg/1Jul 15, 2026Sep 2, 2026
PTC Therapeutics, Inc.DEFLAZACORT 6 mg/1Jul 15, 2026Sep 2, 2026
PTC Therapeutics, Inc.DEFLAZACORT 18 mg/1Jul 15, 2026Sep 2, 2026
PTC Therapeutics, Inc.DEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.DEFLAZACORT 30 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.DEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.DEFLAZACORT 6 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.DEFLAZACORT 18 mg/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals (USA) Inc.DEFLAZACORT 36 mg/1Jul 15, 2026Sep 2, 2026
Doppel Farmaceutici S.r.l.DEFLAZACORT 36 mg/1Aug 28, 2026Aug 31, 2026
Doppel Farmaceutici S.r.l.DEFLAZACORT 30 mg/1Aug 28, 2026Aug 31, 2026
Doppel Farmaceutici S.r.l.DEFLAZACORT 18 mg/1Aug 28, 2026Aug 31, 2026
Upsher-Smith Laboratories, LLCDEFLAZACORT 6 mg/1Jul 15, 2026Aug 31, 2026
Upsher-Smith Laboratories, LLCDEFLAZACORT 18 mg/1Jul 15, 2026Aug 31, 2026
Upsher-Smith Laboratories, LLCDEFLAZACORT 30 mg/1Jul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Jaythari — NDC 81806-0176-30," retrieved September 3, 2026, https://drugdashboards.com/drug/81806017630.

Free to cite with attribution — see how the data is put together.